$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – VINC, VCSA, MRNS, MHLD
02. Januar 2025 17:30 ET
|
Monteverde & Associates PC
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by...
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
27. Dezember 2024 16:05 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
04. Dezember 2024 06:45 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports Third Quarter 2024 Financial Results
12. November 2024 09:00 ET
|
Vincerx Pharma, Inc.
Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed...
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
07. Oktober 2024 16:05 ET
|
Vincerx Pharma, Inc.
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s potential and validating the VersAptx™...
Vincerx Pharma Reports Second Quarter 2024 Financial Results
08. August 2024 16:30 ET
|
Vincerx Pharma, Inc.
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected...
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
14. Mai 2024 16:15 ET
|
Vincerx Pharma, Inc.
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug...
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
26. April 2024 00:27 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock...
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
25. April 2024 16:01 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying...
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
08. April 2024 16:30 ET
|
Vincerx Pharma, Inc.
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic...